MONDAY, Sept. 21, 2020 -- An immunotherapy drug significantly improved survival in patients with the most common type of bladder cancer, according to a new study. About 550,000 new cases of bladder cancer are diagnosed worldwide each year, making...

MONDAY, Sept. 21, 2020 -- An immunotherapy drug significantly improved survival in patients with the most common type of bladder cancer, according to a new study. About 550,000 new cases of bladder cancer are diagnosed worldwide each year, making...

MONDAY, Sept. 21, 2020 -- An immunotherapy drug significantly improved survival in patients with the most common type of bladder cancer, according to a new study. About 550,000 new cases of bladder cancer are diagnosed worldwide each year, making it...

Researchers at the University of Bern have discovered a mechanism in the body’s own immune system which is responsible for the maturation and activation of immune cells.

For most people, there is no scarier diagnosis than that of cancer. While treatments including chemotherapy and radiotherapy have been used since the 1940s and late 1800s, respectively, immunotherapy has more recently emerged as a viable and successful approach to cancer treatment.

An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.

Lymphomas are a diverse group of cancers of the immune system, which is the body's primary defense against autoimmune disease, infections, and malignancy.

A team of scientists led by a researcher at the Case Western Reserve University School of Medicine is

One of the challenges in the design of confirmatory trials is to deal with uncertainties regarding the optimal target population for a novel drug. Adaptive enrichment designs (AED) which allow for a data-driven selection of one or more pre-specified biomarker subpopulations at an interim analysis have been proposed in this setting but practical case studies of AEDs are still relatively rare. We present the design of an AED with a binary endpoint in the highly dynamic setting of cancer immunotherapy. The trial was initiated as a conventional trial in early triple-negative breast cancer but amended to an AED based on emerging data external to the trial suggesting that PD-L1 status could be a predictive biomarker. Operating characteristics are discussed including the concept of a minimal detectable difference, that is, the smallest observed treatment effect that would lead to a statistically significant result in at least one of the target populations at the interim or the final analysis,

Research into ways of tweaking the body’s cellular defences has huge clinical potential

Research into ways of tweaking the body’s cellular defences has huge clinical potential

A team of scientists led by a researcher at the Case Western Reserve University School of Medicine is making strides to fight deadly metastatic breast cancer by combining nanotechnology with immunotherapy.

Cancer remains one of the most difficult and deadly challenges in human health, affecting Kentuckians at a higher rate than residents of any other state and killing more than 600,000 people each year in the U.S. alone.

Scientists have succeeded in neutralizing a molecule that blocks the immune system against cancer. The researchers discovered that this new immunotherapy increases the action of another well-known but not always effective immunotherapy, and that it makes tumor regression possible.

Cancer immunotherapy is the manipulation of the immune responses naturally present in the human body to fight cancer.

For artificial intelligence (AI) tools being developed at Case Western Reserve University to have impact in the fight

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -; immune checkpoint blockade.

Researchers designed DLnano-vaccines displaying 60 copies of protein parts derived from the melanoma-specific antigens Trp2 and Gp100 and tested these in mouse models of melanoma, observing prolonged survival that depended on CD8 T cell activation both in therapeutic and prophylactic settings.

For Artificial Intelligence (AI) tools being developed at Case Western Reserve University to have impact in the fight against cancer, they're going to have to be validated in rigorous human clinical trials.

Scientists have combined two potent immunotherapies -- an oncolytic virus and chimeric antigen receptor (CAR) T cell therapy -- to target and eradicate solid tumors that are otherwise difficult to treat with CAR T therapy alone.

If cancer is a series of puzzles, a new study pieces together how several of those puzzles connect to form a bigger picture.

Researchers have added to evidence that a gene responsible for turning off a cell's natural 'suicide' signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies that use the immune system to fight cancer.

Mosaic ImmunoEngineering Inc., a private biotechnology company based in Novato, California, has signed a two-year option agreement with

Johns Hopkins Medicine researchers have added to evidence that a gene responsible for turning off a cell's natural "suicide" signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies that use the immune system to fight cancer.

A recent study published in the journal Nature Medicine, led by researchers Todd Allen, PhD, a professor of Medicine at Harvard Medical School and group leader at the Ragon Institute of MGH, MIT and Harvard, and Jim Riley, PhD, a professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, describes a new Dual CAR T cell immunotherapy that can help fight HIV infection.

A team with the participation of researchers from the Spanish National Research Council has designed new hydrogels that allow the culture of T-cells or T-lymphocytes, cells of the immune system that are used in cancer immunotherapy since they have the capacity to destroy tumor cells.

A recent study describes a new Dual CAR T cell immunotherapy that can help fight HIV infection.

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed. This advance in precision medicine will allow clinicians to tailor treatments specifically to patients and avoid treatment paths that are unlikely to be successful.

Immunotherapy is a promising technology for cancer treatment. Essentially, body’s own immune system is taught how to recognize

The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule.

The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system.

Immunotherapies for cancer — treatments that prime the immune system to attack tumors — are valuable weapons in

Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.

Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to

Cancer immunotherapy -- empowering a patient's own immune system to clear away tumors on its own -- holds great promise for some patients. But for other patients, immunotherapy just doesn't work.

Researchers discovered that tumor cells in younger and female patients accumulate cancer-causing mutations that are more poorly presented to the immune system, better enabling tumors to escape detection and clearance.

Immunotherapies for cancer -- treatments that prime the immune system to attack tumors -- are valuable weapons in the anti-cancer arsenal. But some cancers are more difficult to target with this strategy than others. Today, scientists report a new immunotherapy that dramatically extends the survival of mice that have triple negative breast tumors, a difficult-to-treat form of cancer.

Immunotherapies for cancer -; treatments that prime the immune system to attack tumors -; are valuable weapons in the anti-cancer arsenal. But some cancers are more difficult to target with this strategy than others.

Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells. However, in the more than 20 years since their use began, the molecular mechanisms that underlie this therapy are still little understood. For the first time, scientists have observed the interaction between therapeutic antibodies and their target protein.

Immunotherapy has revolutionized cancer treatment by stimulating the patient’s own immune system to attack cancer cells, yielding remarkably

How a protein implicated in Alzheimer’s could enhance cancer immunotherapy aliu Wed, 08/12/2020 - 07:42

Working with an international team of researchers, HonorHealth Research Institute and the Translational Genomics Research Institute, an affiliate of City of Hope, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, Nature Medicine.

Immunotherapy has revolutionized cancer treatment by stimulating the patient's own immune system to attack cancer cells, yielding remarkably quick and complete remission in some cases. But such drugs work for less than a quarter of patients because tumors are notoriously adept at evading immune assault.

In a mouse study, researchers have found that an antibody that targets the protein TREM2 empowers tumor-destroying immune cells and improves the effectiveness of cancer immunotherapy.

A test that detects changing levels of tumour fragments in the blood may be an easy, non-invasive and

Cancer immunotherapy — a treatment that better enables a patient’s own immune system to attack tumors — has

A new type of immunotherapy for the skin cancer malignant melanoma shows promising results. Three severely ill patients are now long-term survivors.

Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the top-tier journal Cancer Research by investigators at the George Washington University (GW) Cancer Center.

Cancer immunotherapy -; a treatment that better enables a patient's own immune system to attack tumors -; has shown great potential against some cancers. Yet immunotherapy doesn't work against all tumor types, and many patients who initially respond later develop resistance and relapse.

Scientists at UCL have discovered new biomarkers, which may identify those people with Type 1 diabetes who would benefit from the immunotherapy drug Abatacept, a finding which could eventually help thousands manage the disease more effectively.

A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

A study has revealed that tumours can evade the immune system by telling immune cells to produce immunosuppressive steroids. Researchers from the Wellcome Sanger Institute, Department of Pathology, University of Cambridge, and MRC Cancer Unit, discovered that immune T cells from mouse skin and breast tumours secrete steroids, and that preventing this steroid production reduced growth of tumours in mice.

Researchers have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia.

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer. But immunotherapies don't work in all patients, and researchers have been searching for ways to increase their effectiveness.

Hollings Cancer Center researcher Jessica Thaxton, Ph.D., is the recipient of two grants totaling $3.4 million from the National Cancer Institute for her work in cancer immunotherapy and cell stress, one of which is part of the Cancer Moonshot Initiative on immunometabolism.

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient’s

Adoptive cell transfer immunotherapy is one of the most promising new treatments for people with hard-to-treat cancers.

Tel Aviv University researchers have found that the short time period around tumor removal surgery (the weeks before and after surgery) is critical for the prevention of metastases development, which develop when the body is under stress.

Researchers from Monash University’s Institute of Pharmaceutical Sciences are paving the way for accessible and affordable cancer treatment by using powerful nanoscale tools to overcome the high costs and long lead-times associated with one of the world’s newest forms of immunotherapy: CAR-T cell therapy.

MONDAY, July 20, 2020 -- Immunotherapy for cancer patients with COVID-19 appears safe, a preliminary study suggests. The treatments activate a person's immune system against cancer. Researchers have been wary, because many COVID-19 complications...

Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer.

Initial findings from a new study show that immunotherapy for cancer won't worsen complications for patients with the disease and COVID-19.

While immunotherapy -- a form of treatment that uses the body's immune system to recognize, attack and kill tumor cells -- has given hope to people across the globe, it fails in a significant proportion of cancer patients.

Aichi Cancer Center(1) and NEC Corporation (NEC; 6701) today announced the launch of fundamental research aiming to realize

Our immune system ought to be able to recognize and kill tumor cells. However, many tumors deceive the immune system. For example, they induce the so-called immune checkpoints of T-cells to shut down immune responses. In the journal Angewandte Chemie, scientists have now introduced a new approach for immunological tumor treatment. Their method is based on the specific blockade of an immune checkpoint by a stable "mirror-image" peptide.

The National Comprehensive Cancer Network today announced the completion of the new NCCN Guidelines for Patients®: Immunotherapy Side Effects series, with the publication of a book focused on chimeric antigen receptor (CAR) T-cell therapy. This closely follows the publication of a separate book on immune checkpoint inhibitors, both created with support from the NCCN Foundation®.

Manipulating proteins to make 'cold' tumors responsive to immunotherapies aliu Thu, 06/25/2020 - 07:49

National Institutes of Health investigators and colleagues have discovered that when the immune system first responds to infectious

NIH investigators and colleagues have discovered that when the immune system first responds to infectious agents such as viruses or bacteria, a natural brake on the response prevents overactivation.

published in CANCER indicates that taking vitamin D supplements may help prevent a potentially serious side effect of a revolutionary form of anti-cancer therapy.

The particles will be produced using 3D-bioprinting, enabling them to be released at specified intervals, instead of a continuous slow release.

Acute myeloid leukemia (AML) is a hematological malignancy which incidence increases with age, that is biologically, phenotypically, and

Acute myeloid leukemia is a hematological malignancy which incidence increases with age, that is biologically, phenotypically, and genetically very heterogeneous.

UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.

Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work badams Mon, 06/15/2020 - 08:16

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.

Cancer researchers at Children's Hospital of Philadelphia have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.

By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), researchers have identified new immune classes of the disease that predict the likelihood of drug resistance and positive responses to immunotherapy.

Researchers at the Chongqing Medical University in China have identified a cytokine that could serve as a potential candidate for treating patients with severe coronavirus disease 2019 (COVID-19).

Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by

MIT engineers have found a way to boost the effectiveness of cancer immunotherapy drugs called checkpoint inhibitors. They showed that if they treated mice with these drugs along with new nanoparticles that stimulate the immune system, the therapy became more powerful than checkpoint inhibitors given alone.

One promising strategy to treat cancer is stimulating the body’s own immune system to attack tumors. However, tumors

A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.

​By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.

Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer.

Why 'hot' kidney tumors don't respond to immunotherapy with PD-1 blockers aliu Thu, 05/28/2020 - 06:41

A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome resistance to the anti-PD-1 therapy in a mechanistically-based way.

Researchers of McMaster University and the University of Toronto have developed a promising immunotherapy treatment for a deadly form of adult brain cancer called glioblastoma.

Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania and other institutions.

Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020.

Treatment with antibodies purified from donated blood - immune globulin therapy - and steroids restored heart function in the majority of children with COVID-related multi-system inflammatory syndrome, according to new research published yesterday in Circulation, the flagship journal of the American Heart Association.

Treatment with antibodies purified from donated blood - immune globulin therapy - and steroids restored heart function in the majority of children with COVID-related multi-system inflammatory syndrome, according to new research published yesterday in Circulation, the flagship journal of the American Heart Association.

Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns “cold” tumors “hot”. “Cold”, immune-desert tumors are classically immunotherapy-resistant.

A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.